Artificial Blood Development Implications for Military Medicine.

Q3 Medicine
Vanessa R Melanson, Jeremy R Hershfield, Michael Kevin Deegan, Hyeveen Cho, Dion Perinon, Stacey L Bateman, Jason C Barnhill
{"title":"Artificial Blood Development Implications for Military Medicine.","authors":"Vanessa R Melanson,&nbsp;Jeremy R Hershfield,&nbsp;Michael Kevin Deegan,&nbsp;Hyeveen Cho,&nbsp;Dion Perinon,&nbsp;Stacey L Bateman,&nbsp;Jason C Barnhill","doi":"10.55460/OVOP-V2QC","DOIUrl":null,"url":null,"abstract":"<p><p>Massive hemorrhaging remains the most common cause of preventable battlefield deaths. Blood used for trauma care requires a robust donation network, capacity for long-term storage, and extensive and accurate testing. Bioengineering technologies could offer a remedy to these constraints in the form of blood substitutes-fluids that could be transfused into patients to provide oxygen, carry away waste, and aid in coagulation-that would be used in prolonged casualty care and in far-forward settings, overcoming the obstacles of distance and time. The different molecular properties of red blood cells (RBCs), blood substitutes, and platelet replacements contribute to their respective utilities, and each type is currently represented in ongoing clinical trials. Hemoglobin oxygen carriers (HBOCs) are the most advanced RBC replacements, many of which are currently being evaluated in clinical trials in the United States and other countries. Despite recent advancements, challenges remaining in the development of blood alternatives include stability, oxygen capacity, and compatibility. The continued research and investment in new technologies has the potential to significantly benefit the treatment of life-threatening emergency injuries, both on the battlefield and in the civilian sector. In this review, we discuss military blood-management practices and military-specific uses of individual blood components, as well as describe and analyze several artificial blood products that could be options for future battlefield use.</p>","PeriodicalId":53630,"journal":{"name":"Journal of special operations medicine : a peer reviewed journal for SOF medical professionals","volume":" ","pages":"63-69"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of special operations medicine : a peer reviewed journal for SOF medical professionals","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55460/OVOP-V2QC","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Massive hemorrhaging remains the most common cause of preventable battlefield deaths. Blood used for trauma care requires a robust donation network, capacity for long-term storage, and extensive and accurate testing. Bioengineering technologies could offer a remedy to these constraints in the form of blood substitutes-fluids that could be transfused into patients to provide oxygen, carry away waste, and aid in coagulation-that would be used in prolonged casualty care and in far-forward settings, overcoming the obstacles of distance and time. The different molecular properties of red blood cells (RBCs), blood substitutes, and platelet replacements contribute to their respective utilities, and each type is currently represented in ongoing clinical trials. Hemoglobin oxygen carriers (HBOCs) are the most advanced RBC replacements, many of which are currently being evaluated in clinical trials in the United States and other countries. Despite recent advancements, challenges remaining in the development of blood alternatives include stability, oxygen capacity, and compatibility. The continued research and investment in new technologies has the potential to significantly benefit the treatment of life-threatening emergency injuries, both on the battlefield and in the civilian sector. In this review, we discuss military blood-management practices and military-specific uses of individual blood components, as well as describe and analyze several artificial blood products that could be options for future battlefield use.

人工血液开发对军事医学的启示。
大规模出血仍然是可预防的战场死亡的最常见原因。用于创伤护理的血液需要强大的捐赠网络、长期储存能力以及广泛准确的检测。生物工程技术可以以血液替代液的形式为这些限制提供补救措施,血液替代液可以输注到患者体内,提供氧气,带走废物,并有助于凝血,用于长期伤员护理和远期环境,克服距离和时间的障碍。红细胞(RBCs)、血液替代品和血小板替代品的不同分子特性有助于它们各自的用途,目前每种类型都在正在进行的临床试验中有代表性。血红蛋白氧载体(HBOC)是最先进的红细胞替代品,其中许多目前正在美国和其他国家的临床试验中进行评估。尽管最近取得了进展,但血液替代品的开发仍面临挑战,包括稳定性、氧气容量和兼容性。对新技术的持续研究和投资有可能大大有利于在战场和民用部门治疗危及生命的紧急伤害。在这篇综述中,我们讨论了军事血液管理实践和个别血液成分的军事特定用途,并描述和分析了几种可供未来战场使用的人造血液产品。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
91
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信